“The telehealth means I get distance from the hospital so I don’t feel so much like a patient”: A qualitative sub-study examining the acceptability of nurse-led follow-up for ovarian cancer via telehealth using the MOST-S26 to structure consultations.
Rachel Campbell(South Eastern Health and Social Care Trust), Paul A. Cohen(The University of Western Australia), Penelope M. Webb(QIMR Berghofer Medical Research Institute), Michael Friedländer(Prince of Wales Hospital), Val Gebski(The University of Sydney), Rachael L. Morton(University of Sydney), Patsy Yates(Queensland University of Technology), Wanda Lawson(Australia New Zealand Gynaecological Oncology Group), Linda Mileshkin(Peter MacCallum Cancer Centre), Jim Codde(The University of Notre Dame Australia), Tarek Meniawy(St John of God Subiaco Hospital), Angela Ives(The University of Western Australia), Alison H. Brand(The University of Sydney), Phyllis Butow(Royal Prince Alfred Hospital), Sanela Bilic, Megan S Jeon(The University of Sydney), Orla McNally(Royal Women's Hospital), Andreas Obermair(Royal Brisbane and Women's Hospital), Jeffrey C. Goh(The University of Queensland), Madeleine King(The University of Sydney)
Cited by 0
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k